MOR106

DRUG2 trials

Sponsors

Galapagos NV

Conditions

Atopic DermatitisHealthy

Phase 1

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

TerminatedNCT03689829

Galapagos NVAtopic Dermatitis, Healthy

Start: 2018-08-13End: 2020-03-02Updated: 2020-03-18

Phase 2

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

TerminatedNCT03864627

Galapagos NVAtopic Dermatitis

Start: 2019-03-25End: 2020-02-27Updated: 2021-01-05

Related Papers

Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis

Journal of Clinical Medicine2022-12-0610 citations